Venture capital investment in early-stage biotechnology and pharmaceutical startups is seeing exuberance that could be classed as “froth,” but it does not appear to be in bubble territory yet.
Gaithersburg biotech startup Neuraly has raised $36 million for its potential Alzheimer’s disease and Parkinson’s disease treatment, the company announced.
IndieBio is making its way to New York.
The San Francisco-based biotech incubator received a $25 million investment from the state’s government. The move is part of a broader push to support life sciences startups across New York State (h/t The Wall Street Journal).
The University of Pennsylvania’s startup incubator is getting a boost from a big pharmaceutical company.
The First Coast Innovator’s Gathering on Day 1 is focused on tech hubs and companies from the First Coast: DC, MD, PA, NJ, NY, RI, CT, and MA. We encourage all global tech hubs and their constituents to attend.
There’s been more venture capital invested through the first six months of 2018 in the US than any six-month period in recent history, which highlights the new normal in the industry: more capital concentrated into fewer, larger deals. On the exit end of the spectrum, there’s been improved access to the IPO market, particularly for enterprise tech companies.
A startup company spun out of Johns Hopkins says it’s been able to slow the progression of Parkinson’s disease in mice models — and with a fresh infusion of cash, the company is taking the program into human trials.
High-profile investors led by billionaires Bill Gates and Leonard Lauder are throwing their weight behind a “venture philanthropy vehicle” offering more than $30 million in grants for new biomarkers and early diagnostic tests for Alzheimer’s disease.
The Trump administration moved swiftly in the past 24 hours to implement pieces of its plan to bring down drug prices, preparing several significant steps as one of the biggest U.S. drugmakers said it would bring down the cost of some medicines.
Johnson & Johnson Innovation LLC today announced agreement to launch the Johnson & Johnson Innovation, JLABS (JLABS) JPOD @ Philadelphia (JPOD @ Philadelphia) in collaboration with the University of Pennsylvania (Penn) to accelerate healthcare innovation and commercialization in Philadelphia and beyond.